Organigram Global Inc. reported net revenue of $105.8 million [1] during its third-quarter fiscal 2026 earnings call on Aug. 11.
The results demonstrate a significant scaling of operations, though the company continues to struggle with profitability as it expands its international footprint.
Revenue grew by 49% compared to the $70.8 million reported in the same period last year [1]. This performance exceeded the consensus revenue estimate of $68.65 million [8]. The company said much of this growth was due to the consolidation of Sanity Group, which occurred on April 15, 2026 [1].
Sanity Group contributed EUR 24.5 million, approximately $40 million, to the quarterly results [1]. For a full quarter, the contribution from Sanity Group reached EUR 25.5 million [1].
Despite the record revenue, Organigram reported a quarterly loss of $0.05 per share [5]. This figure was higher than the consensus loss estimate of $0.01 per share [6], and the prior year's loss of $0.03 per share [7].
Executives used the call to discuss the current state of the European market. James Yamanaka said, "It is a tight market for the EU‑GMP quality supply into Germany at the moment" [9].
The company used the virtual conference call to provide guidance to shareholders regarding its momentum, and the impact of its recent acquisitions [10].
“Net revenue for Q3 2026 reached $105.8 million”
Organigram's financial trajectory shows a company successfully leveraging acquisitions to drive top-line growth. The integration of Sanity Group has provided a substantial revenue boost and a foothold in the European market. However, the widening loss per share suggests that the costs of this rapid expansion and the complexities of the EU-GMP supply chain are currently outweighing the immediate gains in revenue.
